Bayer on deck with nine abstracts at ASCO

|About: Bayer A.G. ADR (BAYRY)|By:, SA News Editor

Bayer (OTCPK:BAYRY +1.2%) announces nine data presentations at ASCO. Highlights (all times CDT):

Regorafenib: Interim data from CORRELATE study in mCRC: Saturday, June 3 in the am; data from Phase 3 CORRECT study in mCRC: Saturday, June 3 in the am; data from Phase 3 RESORCE study in liver cancer: Saturday, June 3 in the am.

Sorafenib: Interim data from RIFTOS MKI study in thyroid cancer: Monday, June 5 in the pm.

Darolutamide: Data from Phase 3 ODM-201 study in prostate cancer: Monday, June 5 in the pm.

Copanlisib: Data from Phase 2 study in diffuse large B-cell lymphoma: Monday, June 5 in the am.

#ASCO17